Dr. Reddy's Laboratories announces its intent to appeal court decision in preliminary injunction hearing for
Buprenorphine and Naloxone Sublingual Film
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr.
Reddy’s”) today announced its intent to appeal the decision made by the U.S. District Court for the District of New Jersey in a
preliminary injunction hearing with respect to further sales and commercialization of Dr. Reddy’s Buprenorphine and Naloxone
Sublingual Film within the United States.
The company disagrees with the court’s decision, and will vigorously appeal it.
Dr. Reddy’s had announced the receipt of the approval, on June 15, 2018 by one of its wholly owned subsidiaries, from the U.S.
Food and Drug Administration (USFDA) for its Buprenorphine and Naloxone Sublingual Film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12
mg/3 mg, therapeutic equivalent generic version of Suboxone® (buprenorphine and naloxone) sublingual film, in the United States
market.
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical
company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses -
Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of
products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our
major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr.
Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For
more information, log on to: www.drreddys.com
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that
are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause
actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to
statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends",
"anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking
statements. Actual results, performance or events may differ materially from those in such statements due to without limitation,
(i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest
rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii)
changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central
banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues.
The company assumes no obligation to update any information contained herein.
Dr. Reddy’s Laboratories Ltd.
INVESTOR RELATIONS
SAUNAK SAVLA, +91-40-49002135
saunaks@drreddys.com
or
MEDIA RELATIONS
CALVIN PRINTER, +91-40-49002121
calvinprinter@drreddys.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180714005010/en/